Please assess the completion status of the following clinical trial:

Trial Title: MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 to 65 years of age (both inclusive), at the time of informed consent~* Participants diagnosed with RRMS according to McDonald criteria 2010~* Participants have discontinued treatment with dimethyl fumarate (Tecfidera), teriflunomide (Aubagio), glatiramer acetate (Copaxone®), intramuscular IFNβ-1a (Avonex®), pegylated interferon (Plegridy®), subcutaneous IFNβ-1b (Betaferon®) or fingolimod (Gilenya®) within 6 months prior to Visit 1~  * Currently treated with Rebif using RebiSmart 2.0, for a maximum of 6 months prior to Visit 1~ * Participants have a score on the Expanded Disability Status Scale (EDSS) between 0 to 5.0 inclusive~ * Participants willing and able to give informed consent.~Exclusion Criteria:~* Participants have known planned surgical procedures at the time of the informed consent that will prevent adherence to treatment with Rebif through RebiSmart 2.0~* Participants diagnosed with primary progressive, secondary progressive, or progressive relapsing MS~* pregnant or lactating, or planning to become pregnant subjects~* In the opinion of the Investigator has significant renal or hepatic impairment or other significant disease (e.g., cognitive or visual impairment) that would compromise adherence and completion of the study~* Reports any reason that he/she cannot complete the 1 year study~* Participants have a history of hypersensitivity to natural or recombinant interferon, or any other component of the formulation~* Participants who contraindicated for the treatment with subcutaneous IFNβ-1a therapy as per summary of product characteristics or currently approved specific country product information~* Participants have any other factor that in the opinion of the Investigator would make the subject unsuitable for participation in this study~* Participants have significant psychiatric symptoms that, in the opinion of the Investigator, would impact patient ability to comply with treatment recommendations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rebif in Relapsing-Remitting Multiple Sclerosis (RRMS) (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).